ABSTRACT
We studied 14 diabetic patients with type 2 diabetes [9 men and 5 women] in the aim to evaluate their metabolic control when treated with repaglinide while fasting during the month of Ramadan; their mean age was 50.6 +/- 2.2 year and their mean diabetes duration was 6.2 +/- 1. 3 years. We followed closely incidences of diurnal hypoglycemia and post prandial hyperglycemia. Mean glycosylated hemoglobin before Ramadan was 7.3 +/- 0.3% and none of our subjects had micro or macroangiopathy. During Ramadan, patients received repaglinide [l.l +/- 0.1mg at Iftar and 0.8 +/- 0.1mg at Shour] and metformine was continued in the 13 patients who were taking it prior to our study. Mean capillary glycemia at the end of the daily fasting was 1.32 +/- 1.06 g/l compared to 1.19 +/- 0.06 g/l for a mean fasting blood glucose before the month of Ramadan. Their mean postprandial 2H blood glucose after Iftar was 2. 15 +/- 0.17 g/l compared to 1.86 +/- 0.19 g/l for postprandial blood glucose after dinner. The mean blood glucose 2H after Shour was 1.76 +/- 0.20 g/l compared to 1.71 +/- 0.18 g/l for postprandial blood glucose after breakfast. The patients' weight remained stable; Fructosamine increased by 20.2 +/- 25.6 micro mol/l and glycosylated hemoglobin by 0.3 +/- 0.1%. Total food caloric intake and food composition remained unchanged. Only one event of clinical hypoglycemia occurred. Use of repaglinide during Ramadan decreases postprandial hyperglycemia without increasing the risk of diurnal hypoglycemia
Subject(s)
Humans , Male , Female , Carbamates , Piperidines , Fasting , Islam , Hypoglycemia , Hyperglycemia , Blood Glucose , Metformin , Glycated HemoglobinABSTRACT
We assessed the effects of Ramadan fasting on metabolic control, particularly change of HDL-cholesterol in 25 type 2 diabetic patients treated with diet or oral agents, with good metabolic control. Clinical and biochemical parameters and food intake were evaluated 3 weeks before Ramadan, in the fourth week of Ramadan and 3 weeks after Ramadan.There were no changes in body weight and blood pressure nor any metabolic complications. The mean plasma fasting glucose, serum fructosamin and haemoglobin A1c did not change. We found a negative relation between cholesterol intake during Ramadan and the change of HDL-cholesterol. When cholesterol intake was lower than 400 mg/day, plasma HDL-cholesterol increased by 13% at the end of Ramadan and by 23% 3 weeks after Ramadan
Subject(s)
Female , Humans , Male , Middle Aged , Administration, Oral , Blood Glucose/metabolism , Blood Pressure , Cholesterol, Dietary/administration & dosage , Creatinine/metabolism , Fasting/metabolism , Fructosamine/metabolism , Glycated Hemoglobin/metabolism , Hypoglycemic Agents , Time Factors , Uric Acid/metabolismABSTRACT
We evaluated the effects of fasting during Ramadan on nutritional intake and plasma lipoproteins in 20 healthy adults of normal weight. A 5-day food questionnaire was completed for every participant. Clinical investigations, anthropometrical measurements and laboratory analysis were also undertaken. Body weight, blood pressure and blood glucose were not influenced by fasting but there were non-significant modifications in the plasma lipid fractions. The total cholesterol remained unchanged. Total daily energy intake was comparable before, during and after Ramadan despite the decrease in meal frequency during fasting. Thus fasting in Ramadan did not affect dietary intake, clinical, anthropometrical and most biological parameters